- Home
- UAL vs ONC Comparison
UAL vs ONC Comparison
Compare UAL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- ONC
- Stock Information
- Founded
- UAL 1934
- ONC 2010
- Country
- UAL United States
- ONC Switzerland
- Employees
- UAL N/A
- ONC N/A
- Industry
- UAL Air Freight/Delivery Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- UAL Consumer Discretionary
- ONC Health Care
- Exchange
- UAL Nasdaq
- ONC Nasdaq
- Market Cap
- UAL 26.5B
- ONC 31.5B
- IPO Year
- UAL N/A
- ONC N/A
- Fundamental
- Price
- UAL $100.93
- ONC $321.36
- Analyst Decision
- UAL Strong Buy
- ONC Strong Buy
- Analyst Count
- UAL 15
- ONC 9
- Target Price
- UAL $108.00
- ONC $335.78
- AVG Volume (30 Days)
- UAL 5.6M
- ONC 414.0K
- Earning Date
- UAL 07-16-2025
- ONC 08-06-2025
- Dividend Yield
- UAL N/A
- ONC N/A
- EPS Growth
- UAL 13.06
- ONC N/A
- EPS
- UAL 9.98
- ONC N/A
- Revenue
- UAL $57,986,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- UAL $4.40
- ONC $865.19
- Revenue Next Year
- UAL $7.57
- ONC $21.12
- P/E Ratio
- UAL $10.12
- ONC N/A
- Revenue Growth
- UAL 4.23
- ONC 47.33
- 52 Week Low
- UAL $40.96
- ONC $170.99
- 52 Week High
- UAL $116.00
- ONC $321.69
- Technical
- Relative Strength Index (RSI)
- UAL 70.98
- ONC N/A
- Support Level
- UAL $86.98
- ONC N/A
- Resistance Level
- UAL $100.06
- ONC N/A
- Average True Range (ATR)
- UAL 2.78
- ONC 0.00
- MACD
- UAL 1.00
- ONC 0.00
- Stochastic Oscillator
- UAL 97.17
- ONC 0.00
About UAL United Airlines Holdings Inc.
United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.